Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Hold” by the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $36.95.

Several equities analysts recently weighed in on ASND shares. Wedbush reissued an “outperform” rating and set a $10.71 price objective (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Bank of America Corporation reissued a “buy” rating and set a $36.00 price objective (up previously from $34.00) on shares of Ascendis Pharma A/S in a research report on Monday, September 25th. Credit Suisse Group reissued an “outperform” rating and set a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wells Fargo & Company reissued a “buy” rating and set a $51.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Zacks Investment Research cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd.

Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 2,541 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Ascendis Pharma A/S in the 1st quarter valued at approximately $144,000. Bank of America Corp DE raised its holdings in Ascendis Pharma A/S by 23.6% in the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,020 shares in the last quarter. Aperio Group LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $241,000. Finally, Karp Capital Management Corp acquired a new position in Ascendis Pharma A/S in the 1st quarter valued at approximately $203,000. 64.00% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Ascendis Pharma A/S (ASND) Receives Consensus Recommendation of “Hold” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/ascendis-pharma-as-asnd-receives-consensus-recommendation-of-hold-from-analysts.html.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.24). The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.78 million. Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The business’s revenue was down 61.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.53) EPS.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.